Drug Trial Radar · NCT00997204
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
151
Actual
Start
Sep 25, 2009
Primary completion
Jun 22, 2011
Study completion Jun 22, 2011
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Jerini AG
- First posted
- Oct 19, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.
Conditions
- Hereditary Angioedema
Interventions
IcatibantDrug
Single subcutaneous injection of icatibant, 30 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events in Self-treatment of Acute HAE Attacks With s.c. Injections of IcatibantTime frame: 7 days from the beginning of each phase
Locations
26 sites in 10 countries. Site status is shown where the registry gives one.
Hospital Britanico Unidad de Alergia
Buenos Aires, Argentina
Universitätsklinik für Dermatologie und Venerologie
Graz, Austria
Odense Universitetshospital-OUH
Odense, I Og Alergicentret, Denmark
Centre Hospitalier Universitaire/ Service de Dermatologie
Angers, Angers Cedex 09, France
Hospital Edouaed Herriot
Lyon, Cedex 03, France
Clinique Universitaire de Medicine/ Centre National de reference
Grenoble, Grenoble Cedex 09, France
Hopital Claude Huriex/ Service de medicine interne
Lille, Lille Cedex, France
Hopital Europeen Georges Pompidou Immunologie Clinique
Paris, Paris Cedex 15, France
Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, Charité
Berlin, Germany
Universitäts-Hals-Nasen-Ohren-Klinik Essen, Universität Duisburg-Essen
Essen, Germany
Klinkum der Johann Wolfgang Goethe-Universitat
Frankfurt am Main, Germany
Hautklinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität
Mainz, Germany
Bnai-Zion M.C. Clinical Immunology and Allergy Division
Haifa, Israel
Tel Aviv Sourasky Medical Center - Allergy Unit
Tel Aviv, Israel
The Chaim Sheba Medical Center, The Allergy and Clinical Immunology Unit
Tel HaShomer, Israel
Ospedale Luigi Sacco
Milan, Italy
Universita degli Studi di Napoli 'Federico II'
Naples, Italy
Hospital Universitario Vall de Hebrón / Sección de Alergia, Escola Infermeria
Barcelona, Spain
Hospital General Universitario Gregorio Maranon
Madrid, Spain
Hospital Universitario La Paz, Servicio de Alergia
Madrid, Spain
Hospital Universitario La Fe, Servicio de Alergia
Valencia, Spain
Luzerner Kantonsspital
Lucerne, Switzerland
Universitätsspital Zürich / Dermatologische Klinik
Zurich, Switzerland
Southmead Hospital, Department of Immunology
Bristol, United Kingdom
Barts & The London NHS Trust, Pathology and Pharmacy Building
London, United Kingdom
Derriford Combined Laboratory, Department of Clinical Immunology & Allergy
Plymouth, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.